This collection of technologies covers powerful diagnostic technologies spanning liquid biopsy, molecular profiling, imaging and immunoassays for applications in cancer and other diseases. Key assets enable early detection, prediction of treatment response, patient stratification and the development of companion diagnostics across multiple indications including breast, ovarian, colorectal and hematologic cancers.
The portfolio features the work of renowned Stanford researchers including Christina Curtis, Michael Snyder, Garry Nolan, and Howard Chang.